Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1997
Business Overview: Neurocrine is a neuroimmunology company focused on discovering and developing therapeutics for central nervous and immune system disorders, including anxiety, depression, Alzheimer's disease, obesity, and multiple sclerosis. The company has no commercial products and relies on strategic alliances with Janssen Pharmaceutica, Novartis, and Eli Lilly for funding and development. It also operates a research affiliate, Neuroscience Pharma (NPI) Inc., in Canada.
Key Financial Metrics
| Metric (in thousands) | 1997 | 1996 |
|---|---|---|
| Total Revenues | $26,144 | $19,216 |
| Net Income (Loss) | $5,127 | $5,874 |
| Earnings Per Share (Basic) | $0.30 | $0.39 |
| Operating Expenses | $25,552 | $16,266 |
| Cash & Short-Term Investments | $75,092 | $69,920 |
| Long-Term Debt | $722 | $847 |
| Accumulated Deficit | $(4,895) | $(10,022) |
Revenue Composition (1997): Sponsored research ($11.3M), Milestones ($10.3M), Other revenues ($4.6M). No license fees were recognized in 1997.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 36% to $26.1 million, driven by higher sponsored research and milestone payments from Janssen, Novartis, and Eli Lilly.
- Expense Increase: Operating expenses rose 57% to $25.6 million. Research and development (R&D) expenses increased to $19.9 million due to expanded scientific personnel and clinical activities. General and administrative expenses rose to $5.7 million.
- Net Income Decline: Despite revenue growth, net income decreased 13% to $5.1 million due to the significant increase in R&D expenditures.
- Cash Flow: Net cash provided by operating activities increased to $11.0 million from $6.7 million. Net cash used in investing activities was $7.2 million, primarily for purchasing short-term investments and land.
Guidance, Outlook, and Risks
Outlook: Management believes existing capital resources ($75.1 million in cash/investments) combined with future alliance payments will satisfy funding requirements through 2000. The company expects to incur additional operating losses in the future as R&D activities expand.
Key Risks and Contingencies:
- Development Uncertainty: All product candidates are in research or early clinical stages. No products have received FDA approval. Success depends on clinical trial results and regulatory approvals.
- Strategic Alliance Dependence: The company relies on partners (Janssen, Novartis, Lilly) for funding, clinical development, and commercialization. Termination of these agreements would materially adversely affect the business.
- Patent Risks: Limited patent protection exists for some candidates (e.g., DHEA is not a novel compound). Competitors may develop similar products or challenge patent validity.
- Manufacturing: The company has no manufacturing facilities and relies entirely on third-party contract manufacturers.
Unusual Items: In December 1997, Canadian investors in NPI exercised warrants for 600,502 shares of Neurocrine Common Stock. In February 1998 (subsequent event), the company signed a letter of intent to acquire Northwest NeuroLogic, Inc. for approximately $4.0 million.
Investor Verification Checklist
- Alliance Milestones: Verify the specific development milestones required to trigger future payments from Janssen, Novartis, and Eli Lilly.
- Clinical Trial Status: Confirm the progress and results of Phase I trials for CRF receptor antagonists (Janssen) and Phase II trials for Altered Peptide Ligands (Novartis) and DHEA (NPI).
- Capital Runway: Assess if the $75 million cash balance is sufficient to fund operations through 2000 given the trajectory of increasing R&D expenses.
- Patent Portfolio: Review the status of the ~120 patent applications and the specific scope of protection for key candidates like DHEA and Altered Peptide Ligands.
- Acquisition Terms: Investigate the details and financing of the proposed acquisition of Northwest NeuroLogic, Inc.